vorinostat has been researched along with Brain Stem Neoplasms in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Brain Stem Neoplasms: Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase I/II trial of vorinostat (suberoylanilide hydroxamic acid), an oral histone deacetylase inhibitor, was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) through the Children's Oncology Group (COG) to: 1) determine the recommended phase II dose (RP2D) of vorinostat given concurrently with radiation therapy; 2) document the toxicities of continuing vorinostat as maintenance therapy after radiation; and 3) to determine the efficacy of this regimen by comparing the risk of progression or death with a historical model from past COG trials." | 9.51 | Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. ( Adamson, PC; Adekunle, A; Blaney, SM; Buxton, A; Fouladi, M; Fox, E; Gajjar, A; Kilburn, LB; Krailo, M; Mansur, DB; Su, JM; Weigel, B, 2022) |
| "A phase I/II trial of vorinostat (suberoylanilide hydroxamic acid), an oral histone deacetylase inhibitor, was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) through the Children's Oncology Group (COG) to: 1) determine the recommended phase II dose (RP2D) of vorinostat given concurrently with radiation therapy; 2) document the toxicities of continuing vorinostat as maintenance therapy after radiation; and 3) to determine the efficacy of this regimen by comparing the risk of progression or death with a historical model from past COG trials." | 5.51 | Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. ( Adamson, PC; Adekunle, A; Blaney, SM; Buxton, A; Fouladi, M; Fox, E; Gajjar, A; Kilburn, LB; Krailo, M; Mansur, DB; Su, JM; Weigel, B, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Su, JM | 1 |
| Kilburn, LB | 1 |
| Mansur, DB | 1 |
| Krailo, M | 1 |
| Buxton, A | 1 |
| Adekunle, A | 1 |
| Gajjar, A | 1 |
| Adamson, PC | 1 |
| Weigel, B | 1 |
| Fox, E | 1 |
| Blaney, SM | 1 |
| Fouladi, M | 1 |
1 trial available for vorinostat and Brain Stem Neoplasms
| Article | Year |
|---|---|
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report.
Topics: Astrocytoma; Brain Stem Neoplasms; Child; Diffuse Intrinsic Pontine Glioma; Histone Deacetylase Inhi | 2022 |